95 related articles for article (PubMed ID: 24845030)
1. LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy.
Liu J; Yan P; Jing N; Yang J
Tumour Biol; 2014 Aug; 35(8):8161-7. PubMed ID: 24845030
[TBL] [Abstract][Full Text] [Related]
2. LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy.
Zhang Y; Yang J; Wang J; Guo H; Jing N
Med Oncol; 2014 Aug; 31(8):99. PubMed ID: 25037573
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
[TBL] [Abstract][Full Text] [Related]
4. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
5. SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness.
Tian Y; Jia X; Wang S; Li Y; Zhao P; Cai D; Zhou Z; Wang J; Luo Y; Dong M
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1117-24. PubMed ID: 24752338
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
7. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
12. Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia.
Oram SH; Thoms J; Sive JI; Calero-Nieto FJ; Kinston SJ; Schütte J; Knezevic K; Lock RB; Pimanda JE; Göttgens B
Leukemia; 2013 Jun; 27(6):1348-57. PubMed ID: 23302769
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
Lupini L; Bassi C; Mlcochova J; Musa G; Russo M; Vychytilova-Faltejskova P; Svoboda M; Sabbioni S; Nemecek R; Slaby O; Negrini M
BMC Cancer; 2015 Oct; 15():808. PubMed ID: 26508446
[TBL] [Abstract][Full Text] [Related]
14. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
15. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
16. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer.
Augustine TA; Baig M; Sood A; Budagov T; Atzmon G; Mariadason JM; Aparo S; Maitra R; Goel S
Br J Cancer; 2015 Jan; 112(2):313-8. PubMed ID: 25412235
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab in the treatment of patients with colorectal cancer.
Garrett CR; Eng C
Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
[TBL] [Abstract][Full Text] [Related]
18. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
19. Combinational treatment with microRNA‑133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR.
Zhou J; Lv L; Lin C; Hu G; Guo Y; Wu M; Tian B; Li X
Mol Med Rep; 2015 Oct; 12(4):5407-14. PubMed ID: 26151111
[TBL] [Abstract][Full Text] [Related]
20. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]